| 证券简称：南京医药 | 编号：ls2025-112 | | --- | --- | | 证券代码：600713 | | 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 关于公司募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意南京医药 股份有限公司向不特定对象发行可转换公司债券注册的批复》（证监许可〔2024〕 1736 号）核准，公司向不特定对象发行可转换公司债券 10,814,910 张，每张面 值为人民币 100 元（人民币，下同），募集资金总额为人民币 1,081,491,000.00 元，扣除与发行有关的费用人民币 12,450,077.69 元（不含增值税），募集资金净 额为人民币 1,069,040,922.31 元。 上述募集资金已于 2024 年 12 月 31 日到账，毕马威华振会计师事务所（特 殊普通合伙）对本次募集资金到位情况进 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 2.71% on August 27, with Saily Medical leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Saily Medical (603716) closed at 33.15, down 8.93% with a trading volume of 484,700 shares and a transaction value of 1.671 billion [1] - Other notable declines included HeLiang China (603122) down 5.15%, YaoYigou (300937) down 5.10%, and Guofa Shares (600538) down 4.98% [1] - The overall net outflow of main funds from the pharmaceutical commercial sector was 543 million, while retail investors saw a net inflow of 361 million [1] Fund Flow Analysis - Jiuzhoutong (600998) had a main fund net inflow of 11.8 million, accounting for 18.23% of its total [2] - Dacilin (603233) saw a main fund net inflow of 29.97 million, representing 15.70% [2] - The overall trend indicates a mixed sentiment with main funds withdrawing while retail investors are actively buying [2]

Core Insights - The pharmaceutical commercial sector experienced a slight increase of 0.05% on August 22, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Group 1: Stock Performance - Saily Medical (603716) saw a closing price of 31.52, with a significant increase of 10.02% and a trading volume of 614,300 shares, resulting in a transaction value of 1.861 billion yuan [1] - Guofang Co. (600538) closed at 6.55, up 2.18%, with a trading volume of 218,500 shares [1] - Runda Medical (603108) closed at 18.35, up 1.94%, with a trading volume of 303,900 shares [1] - Other notable stocks include Jiuzhoutong (600998) with a slight increase of 0.55% and Yifeng Pharmacy (603939) with a minimal increase of 0.20% [1] Group 2: Capital Flow - The pharmaceutical commercial sector saw a net inflow of 363 million yuan from main funds, while retail investors experienced a net outflow of 114 million yuan [2] - Speculative funds recorded a net outflow of 249 million yuan [2]

Core Viewpoint - The company has successfully completed the public leasing of its property located at 27 Yanling Lane, Qinhuai District, Nanjing, to Wangu Company, generating stable rental income over a 13-year lease term [1][2]. Group 1: Leasing Process - The company’s board approved the public leasing of the property on June 23-25, 2025, with a starting annual rent of 7.1155 million yuan [1]. - The total area for lease is 13,325.11 square meters, with a lease term of 13 years, including a 6-month rent-free period [1]. - The total expected rental income over the lease term is approximately 97.0973 million yuan, with a 5% increase in rent every three years starting from the fourth year [1][2]. Group 2: Progress of Leasing - The property was publicly listed for lease from July 16 to July 29, 2025, attracting one qualified bidder, Wangu Company [2]. - The final leasing agreement was confirmed on August 20, 2025, with the same annual rent of 7.1155 million yuan and a total lease amount of 97.0973 million yuan [2]. Group 3: Tenant Information - Wangu Company is based in Nanjing, with a registered capital of 66.6667 million yuan and operates in various sectors including enterprise management and property management [3]. - The major shareholder of Wangu Company is Jiangsu Wangu Financial Management Co., Ltd., holding 73.8% of its shares, and there is no related party relationship between the company and Wangu [4]. Group 4: Impact on the Company - The leasing of the property is expected to enhance the company's asset utilization and optimize resource allocation, providing a long-term stable rental income [4].

Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., is issuing its third short-term financing bond for 2024, with a total issuance amount of 50 million yuan [1] - The bond, named "24 Nanjing Pharmaceutical SCP003," has an interest rate of 1.8% and a maturity period of 269 days, with the principal and interest repayment date set for September 12, 2025 [1] - The bond's repayment amount is expected to be approximately 50.66329 million yuan, subject to final confirmation [1] Group 2 - The bond's funds will be transferred to the designated account of the Interbank Market Clearing House before the repayment date, and the clearing house will then distribute the funds to bondholders [1] - In case the repayment date falls on a public holiday, the payment will be postponed accordingly [1] - Bondholders must notify the Interbank Market Clearing House of any changes to their fund transfer paths before the repayment date to avoid any delays in receiving funds [1]

Group 1 - The company, Nanjing Pharmaceutical Co., Ltd., is issuing its second super short-term financing bond for 2025, with a total issuance amount of 50 million yuan [1] - The bond, named "25 Nanjing Pharmaceutical SCP002," has an interest rate of 1.94% and a maturity period of 179 days, with the principal and interest repayment date set for September 12, 2025 [1] - The bond's repayment amount is expected to be 50,475.70 million yuan, subject to final confirmation [1] Group 2 - The bond's funds will be transferred to the designated account of the interbank market clearing house before the repayment date, and the clearing house will then distribute the funds to bondholders [1] - In case the repayment date falls on a public holiday, the payment will be postponed accordingly [1] - Bondholders must notify the clearing house of any changes to their fund transfer paths before the repayment date to avoid any delays in receiving funds [1]

Market Overview - The pharmaceutical commercial sector increased by 0.27% on August 21, with Guofang Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3771.1, up 0.13%, while the Shenzhen Component Index closed at 11919.76, down 0.06% [1] Stock Performance - Guofang Co., Ltd. (600538) closed at 6.41, up 1.91% with a trading volume of 315,600 shares and a transaction value of 202 million yuan [1] - Nanjing Pharmaceutical (600713) closed at 5.39, up 1.70% with a trading volume of 181,000 shares and a transaction value of 96.97 million yuan [1] - Shanghai Pharmaceuticals (601607) closed at 19.20, up 0.95% with a trading volume of 173,600 shares and a transaction value of 333 million yuan [1] - Yifeng Pharmacy (603939) closed at 24.49, up 0.91% with a trading volume of 88,100 shares and a transaction value of 215 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 277 million yuan from institutional investors, while retail investors saw a net inflow of 293 million yuan [2] - The data indicates that institutional investors are withdrawing capital, while retail investors are increasing their investments in the sector [2] Individual Stock Capital Flow - Nanjing Pharmaceutical saw a net inflow of 16.81 million yuan from institutional investors, while retail investors had a net outflow of 4.14 million yuan [3] - Yifeng Pharmacy experienced a net inflow of 15.49 million yuan from institutional investors, with a net outflow of 23.62 million yuan from retail investors [3] - China National Pharmaceutical (600056) had a net inflow of 8.93 million yuan from institutional investors, while retail investors had a negligible net inflow of 0.12 million yuan [3]

证券代码：600713 证券简称：南京医药 编号：ls2025-109 2025 年 6 月 23-25 日，公司第十届董事会临时会议审议通过《关于公司公开 挂牌出租南京市秦淮区延龄巷 27 号房地产的议案》。董事会同意公司公开挂牌 出租标的资产，挂牌出租起始年租金租赁价格为 711.55 万元/年（人民币，下同）。 出租总面积 13,325.11 平方米（以实际可租赁面积为准），租赁期限为 13 年（156 个月，免租期为 6 个月，租赁期前三年均摊）。租金按季支付，租金单价前三年 不变，第四年起开始递增，每三年在上一年租金的基础上递增 5%，租赁期的租 金总收入预计为 9,709.73 万元。最终成交价格及承租人根据公开挂牌结果予以确 定。董事会同时授权公司经营层具体办理上述资产挂牌出租相关事宜。详情请见 公司于 2025 年 6 月 26 日对外披露的编号为 ls2025-093 之《南京医药股份有限公 司关于公开挂牌出租南京市秦淮区延龄巷 27 号房地产的公告》。 二、挂牌进展情况 2025 年 7 月 16 日至 2025 年 7 月 29 日，标的资产在南京市公共资源交易中 心挂牌，公开征集承租人 ...

Core Points - Nanjing Pharmaceutical Co., Ltd. announced the progress of leasing a property located at 27 Yanling Lane, Qinhuai District, Nanjing [1] - The board of directors approved the public listing for lease from June 23 to June 25, 2025, with an initial annual rent of 7.1155 million yuan and a lease term of 13 years, expecting total rental income of 97.0973 million yuan [1] - The solicitation for tenants took place from July 16 to July 29, with only Wangu Enterprise Management Group Co., Ltd. meeting the qualification criteria [1] - On August 20, the company received a confirmation of transaction, with Wangu Company as the lessee at the agreed price of 7.1155 million yuan per year, totaling 97.0973 million yuan [1] - Wangu Company has a registered capital of 66.6667 million yuan and is not related to Nanjing Pharmaceutical [1]

Core Points - Nanjing Pharmaceutical announced the use of 170 million yuan of temporarily idle raised funds to purchase a large corporate time deposit from Minsheng Bank, which matured on August 19, 2025 [2] - The company redeemed the principal of 170 million yuan and earned investment income of 573,800 yuan, which met expectations [2] - The company plans to continue using the same amount of 170 million yuan to purchase another large time deposit from Minsheng Bank with a term of 3 months and an annualized yield of 1.10% [2]